LIXTE Biotechnology Announces A Supported Collaborative Trial To Study LIXTE's First-In-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, In Clear-Cell Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) has announced a Phase 1b collaborative clinical trial to assess the effectiveness of adding Lixte's LB-100 to GSK's dostarlimab in the treatment of ovarian clear cell carcinoma. The trial is sponsored by The University of Texas - MD Anderson Cancer Center and will also be open at Northwestern University's Robert H. Lurie Comprehensive Cancer Center. LIXTE will provide LB-100; GSK will provide dostarlimab and financial support for the clinical trial.
September 20, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LIXTE Biotechnology's announcement of a Phase 1b clinical trial for its LB-100 drug in combination with GSK's dostarlimab could potentially boost investor confidence in the company's research and development capabilities.
The announcement of a new clinical trial is typically seen as a positive development for biotech companies, as it indicates progress in their research and development efforts. This could potentially lead to increased investor confidence in LIXTE Biotechnology, which may positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100